title: Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
abstract: BACKGROUND
  The effect of LSD in humans has been described as occurring in two temporal phases. The behavioral effects in rats also occur in two temporal phases: an initial suppression of exploration followed by increased locomotor activity.
  
  
  OBJECTIVE
  We decided to investigate this phenomenon from the perspective that the pharmacology might have relevance to the neurochemical mechanisms underlying psychosis.
  
  
  METHODS
  Twenty-five male Sprague-Dawley rats were trained to discriminate LSD (186 nmol/kg, 0.08 mg/kg, i.p.) with a 30-min preinjection time (LSD-30, N=12) and LSD (372 nmol/kg, 0.16 mg/kg, i.p.) with a 90-min preinjection time (LSD-90, N=13) from saline, using a two-lever, food-reinforced operant conditioning task.
  
  
  RESULTS
  LSD (186 or 372 nmol/kg, 0.08 or 0.16 mg/kg) given 30 min prior to training produced a cue that was completely antagonized by 5-HT2A antagonists and lasted no longer than 1 h. LSD (372 nmol/kg, 0.16 mg/kg) injected 90 min before training produced a cue that was not fully blocked by 5-HT2A antagonists, but instead was significantly inhibited by haloperidol. In these rats, substitution no longer occurred with the 5-HT2 agonists DOI or LSD (30 min preinjection), but full substitution was obtained with the D2 agonists apomorphine, N-propyldihydrexidine, and quinelorane.
  
  
  CONCLUSIONS
  The discriminative stimulus effect of LSD in rats occurs in two phases, and these studies provide evidence that the later temporal phase is mediated by D2 dopamine receptor stimulation. A second temporal phase that involves dopaminergic pathways would be consistent with the widespread belief that excessive dopaminergic activity may be an underlying cause of paranoid psychosis.
authors.affiliation: Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, Heine Pharmacy Building, 575 Stadium Mall Dr., West Lafayette, IN 47907-2091, USA.
authors.forename: Danuta
authors.initials: D
authors.lastname: Marona-Lewicka
authors.forename: Ronald A
authors.initials: RA
authors.lastname: Thisted
authors.forename: David E
authors.initials: DE
authors.lastname: Nichols
mesh_terms: D000661:Amphetamine / Q000494:pharmacology; D000662:Amphetamines / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D003463:Cues; D004193:Discrimination Learning / Q000187:drug effects; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005464:Fluorobenzenes / Q000494:pharmacology; D006213:Hallucinogens / Q000008:administration & dosage / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D007189:Indans / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D008238:Lysergic Acid Diethylamide / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D010880:Piperidines / Q000494:pharmacology; D011618:Psychotic Disorders / Q000503:physiopathology; D011804:Quinolines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000502:physiology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013997:Time Factors
chemical_list: D000662:Amphetamines; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D018765:Dopamine Uptake Inhibitors; D005464:Fluorobenzenes; D006213:Hallucinogens; D007189:Indans; D010880:Piperidines; D011804:Quinolines; D017448:Receptors, Dopamine D2; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C068879:5-methoxy-6-methyl-2-aminoindan; D008238:Lysergic Acid Diethylamide; D000661:Amphetamine; C079049:volinanserin; D006220:Haloperidol; D001058:Apomorphine; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine; C047726:quinelorane
references.citation: Pharmacol Biochem Behav. 1999 Oct;64(2):283-93
references.pmid: 10515304
references.citation: Life Sci. 1984 Dec 17;35(25):2505-11
references.pmid: 6513725
references.citation: Pharmacol Biochem Behav. 1986 Feb;24(2):407-15
references.pmid: 3006090
references.citation: Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73
references.pmid: 8935801
references.citation: J Med Chem. 1993 Aug 20;36(17):2519-25
references.pmid: 8355253
references.citation: Eur J Pharmacol. 1983 Jul 22;91(2-3):189-96
references.pmid: 6617740
references.citation: Eur J Pharmacol. 1982 Jul 30;81(4):595-602
references.pmid: 7117388
references.citation: Life Sci. 1982 Jun 14;30(24):2057-62
references.pmid: 7109835
references.citation: J Pharmacol Exp Ther. 2002 Jun;301(3):1166-78
references.pmid: 12023552
references.citation: Neuropharmacology. 1997 Oct;36(10):1471-5
references.pmid: 9423936
references.citation: Pharmacol Biochem Behav. 1988 Jul;30(3):617-24
references.pmid: 3211970
references.citation: Psychopharmacology (Berl). 1995 Apr;118(4):401-9
references.pmid: 7568626
references.citation: Eur J Pharmacol. 1994 Jun 2;258(1-2):1-13
references.pmid: 7925587
references.citation: NIDA Res Monogr. 1994;146:157-82
references.pmid: 8742798
references.citation: Eur J Pharmacol. 1984 Jul 20;102(3-4):541-4
references.pmid: 6489439
references.citation: Pharmacol Biochem Behav. 2003 Feb;74(3):713-21
references.pmid: 12543238
references.citation: Psychopharmacology (Berl). 1982;77(2):179-85
references.pmid: 6812137
references.citation: Eur J Pharmacol. 1985 Jan 22;108(2):179-86
references.pmid: 3156756
references.citation: Psychopharmacology (Berl). 1991;105(1):69-76
references.pmid: 1745714
references.citation: Synapse. 1987;1(2):133-52
references.pmid: 2905529
references.citation: Mol Pharmacol. 1982 Mar;21(2):301-14
references.pmid: 7099138
references.citation: J Neurochem. 2001 Mar;76(5):1521-31
references.pmid: 11238736
references.citation: Pharmacol Biochem Behav. 1999 Oct;64(2):251-6
references.pmid: 10515299
references.citation: Neuropharmacology. 1978 Apr-May;17(4-5):257-63
references.pmid: 652138
references.citation: Psychopharmacology (Berl). 1989;98(3):321-9
references.pmid: 2501811
references.citation: J Pharmacol Exp Ther. 1982 Apr;221(1):206-14
references.pmid: 7062283
references.citation: Psychopharmacology (Berl). 1995 May;119(2):239-45
references.pmid: 7659772
references.citation: Eur J Pharmacol. 1994 Oct 13;264(1):99-102
references.pmid: 7530204
references.citation: Psychopharmacology (Berl). 1990;100(1):13-8
references.pmid: 2296621
references.citation: Pharmacol Biochem Behav. 1980 Oct;13(4):549-54
references.pmid: 6107936
references.citation: Pharmacol Ther. 2004 Feb;101(2):131-81
references.pmid: 14761703
references.citation: Psychopharmacology (Berl). 1982;76(2):130-5
references.pmid: 6805022
references.citation: Pharmacol Biochem Behav. 1999 Oct;64(2):353-8
references.pmid: 10515312
references.citation: J Med Chem. 1990 Jun;33(6):1756-64
references.pmid: 1971308
references.citation: J Pharmacol Exp Ther. 1949 Jun;96(2):99-113
references.pmid: 18152921
references.citation: Psychopharmacology (Berl). 1990;100(3):417-25
references.pmid: 2138338
references.citation: J Pharmacol Exp Ther. 1989 Oct;251(1):238-46
references.pmid: 2571717
references.citation: J Psychopharmacol. 1998;12(3):289-304
references.pmid: 10958257
references.citation: Neuropharmacology. 1983 Aug;22(8):1001-5
references.pmid: 6621823
references.citation: Psychopharmacology (Berl). 1989;97(2):206-12
references.pmid: 2471220
references.citation: Neuropsychopharmacology. 1999 Aug;21(2 Suppl):106S-115S
references.pmid: 10432496
references.citation: Behav Neurosci. 1985 Oct;99(5):881-900
references.pmid: 3843306
references.citation: Biosci Rep. 2001 Dec;21(6):691-710
references.pmid: 12166820